The aims of this study were (1) to assess cross-sectionally the associations between Hb levels and some 20 key metabolic parameters, obesity-related peptides and ambulatory blood pressure (ABP) measurements in middle-age (average age 51 years) and senescence (average age 72 years), (2) evaluate in a cross-sectional design Hb levels as a risk factor for fatty liver disease, and in a longitudinal design evaluate the role of Hb levels (3) in prediction of the development of impaired glucose metabolism and (4) as a risk factor for CVD events and -related mortality and total mortality. This evidence concerns the gene GSTM1 and metabolic process.